An Exhausting Emulsion - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

An Exhausting Emulsion

Equipment and Processing Report

Untitled Document

Q: We are making an emulsion using a high-shear in-line mixer. First we prepare the aqueous phase, which includes an emulsifying agent and the active ingredient. Then we add the discontinuous phase, which comprises organic solvents and a monomer, to the vessel, and the in-line mixer is used in a recirculation line to form the emulsion. It’s a 60-gal batch, and it’s taking nearly an hour to get the results we’re looking for. We have tried changing the in-line mixer’s workheads to a two-stage configuration, but it doesn’t affect the mixing time. Where are we going wrong?

A: If you’re adding the discontinuous phase to the aqueous phase in the vessel, the chances are that your in-tank agitation is the problem. The agitator blades are probably positioned near the base of the vessel, which is running fairly slow to avoid aeration because oxidation can damage the active ingredient. But as you add the discontinuous phase and the liquid level rises in the vessel, the agitator won’t be capable of premixing the two phases. Instead, the in-line mixer is drawing the aqueous phase from the bottom of the vessel and recirculating it back into the top, while the solvents remain on the surface. Switching to a two-stage in-line mixer will increase shear, but not solve the problem, as you experienced. The ideal way to prepare an emulsion of this sort is to add the discontinuous phase to the recirculation loop through a manifold just before the in-line mixer, so that both phases are mixed on contact in the mixer’s high-shear zone. However, if you have to add the two phases to each other in the vessel, make sure the in-tank agitator is premixing them properly. Speeding it up as the liquid level rises to maintain the required in-tank movement should allow it to form a rough premix. The in-line mixer will then be able to subject this premix to intense shear and reduce the droplet size to form a finely dispersed, stable emulsion more quickly.

—Peter Matthews, technical manager of Silverson Machines

 

If you have a problem with your equipment or process, an industry expert may have the solution. Please send your question to Erik Greb, editor of Equipment and Processing Report, and we may be able to provide an answer in a future issue. All questions will remain anonymous.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Equipment and Processing Report,
Click here